MEK inhibitors have received attention due their allosteric mechanism of action, which confers extreme specificity, and their demonstrated efficacy in melanomas and colon cancers expressing activated B-RAF [6], [7]. Here, MAP2K7 is linked to malignant colon neoplasm.